Literature DB >> 23474043

Neocortical β-amyloid area is associated with dementia and APOE in the oldest-old.

Daniel J Berlau1, María M Corrada, John L Robinson, Felix Geser, Steven E Arnold, Virginia M-Y Lee, Claudia H Kawas, John Q Trojanowski.   

Abstract

OBJECTIVE: Apolipoprotein E (APOE) ε2 carriers may be protected from dementia because of reduced levels of cortical β-amyloid. In the oldest-old, however, APOE ε2 carriers have high β-amyloid plaque scores and preserved cognition. We compared different measures of β-amyloid pathology across APOE genotypes in the oldest-old, and their relationship with dementia.
METHODS: The study included 96 participants from The 90+ Study. Using all information, dementia diagnoses were made. Neuropathological examination included staging for amyloid plaques and β-amyloid cortical percent area stained by NAB228 antibody.
RESULTS: Both APOE ε2 and APOE ε4 carriers had high Consortium to Establish a Registry for Alzheimer's Disease plaque scores. However, APOE ε2 carriers had low cortical β-amyloid percent areas. β-amyloid percent area was associated with dementia across APOE genotypes.
CONCLUSIONS: Lower levels of percent area in APOE ε2 carriers may reflect lower total β-amyloid and may contribute to APOE ε2 carriers' decreased risk of dementia, despite high β-amyloid plaque scores. The relationship between β-amyloid plaques and dementia in the oldest-old may vary by APOE genotype.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer; Apolipoprotein E; Beta-amyloid; Dementia; Oldest-old

Mesh:

Substances:

Year:  2013        PMID: 23474043      PMCID: PMC3971646          DOI: 10.1016/j.jalz.2012.11.011

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  23 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype.

Authors:  C F Lippa; T W Smith; A M Saunders; C Hulette; D Pulaski-Salo; A D Roses
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

Review 4.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

5.  Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions.

Authors:  T G Ohm; H Scharnagl; W März; J Bohl
Journal:  Acta Neuropathol       Date:  1999-09       Impact factor: 17.088

6.  Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians.

Authors:  C M Morris; R Benjamin; A Leake; F K McArthur; J M Candy; P G Ince; A Torvik; E Bjertness; J A Edwardson
Journal:  Neurosci Lett       Date:  1995-12-01       Impact factor: 3.046

7.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.

Authors:  E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

8.  Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.

Authors:  P Tiraboschi; L A Hansen; E Masliah; M Alford; L J Thal; J Corey-Bloom
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.

Authors:  T Polvikoski; R Sulkava; M Haltia; K Kainulainen; A Vuorio; A Verkkoniemi; L Niinistö; P Halonen; K Kontula
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

View more
  6 in total

1.  APOEε2 is associated with milder clinical and pathological Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Rebecca A Betensky; Bradley T Hyman
Journal:  Ann Neurol       Date:  2015-06       Impact factor: 10.422

2.  Predictors of Optimal Cognitive Aging in 80+ Women: The Women's Health Initiative Memory Study.

Authors:  Joseph S Goveas; Stephen R Rapp; Patricia E Hogan; Ira Driscoll; Hilary A Tindle; J Carson Smith; Shelli R Kesler; Oleg Zaslavsky; Rebecca C Rossom; Judith K Ockene; Kristine Yaffe; JoAnn E Manson; Susan M Resnick; Mark A Espeland
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-03       Impact factor: 6.053

3.  Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life.

Authors:  Lindsey I Sinclair; Seth Love
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study.

Authors:  Anette Hall; Timo Pekkala; Tuomo Polvikoski; Mark van Gils; Miia Kivipelto; Jyrki Lötjönen; Jussi Mattila; Mia Kero; Liisa Myllykangas; Mira Mäkelä; Minna Oinas; Anders Paetau; Hilkka Soininen; Maarit Tanskanen; Alina Solomon
Journal:  Alzheimers Res Ther       Date:  2019-01-22       Impact factor: 6.982

Review 5.  Diagnosis and Management of Cognitive Concerns in the Oldest-Old.

Authors:  Candace Borders; Seyed Ahmad Sajjadi
Journal:  Curr Treat Options Neurol       Date:  2021-03-26       Impact factor: 3.598

6.  Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease.

Authors:  V Velickaite; V Giedraitis; K Ström; I Alafuzoff; H Zetterberg; L Lannfelt; L Kilander; E-M Larsson; M Ingelsson
Journal:  BMC Geriatr       Date:  2017-09-08       Impact factor: 3.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.